Q-omics provides the consensus-scored FAM199X profile across patient tissues and cancer cell-line models. FAM199X expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, FAM199X is differentially expressed in 13, with the highest sampling consensus in BLCA. Additionally, FAM199X RNA expression shows 20,860 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight ACC, BLCA, and UVM as cancer lineages where FAM199X shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FAM199X — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FAM199X survival associations across molecular data types. FAM199X RNA expression shows survival associations in the most cancer types (21), followed by mutation status (3) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FAM199X RNA expression–survival associations across cancer types. High FAM199X expression shows unfavorable associations in MESO, LIHC, PAAD and BRCA, but favorable associations in ACC and LUAD. The ACC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .005). Together, the overview and detailed table identify ACC as the clearest survival context for FAM199X RNA expression.
This table summarizes FAM199X tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 2. The strongest signals are observed in BLCA for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for FAM199X. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FAM199X shows lower tumor expression in THCA and higher tumor expression in BLCA, HNSC, LIHC, STAD and KIRP. The BLCA box plot shows higher FAM199X RNA expression in tumor versus normal tissue (log2 FC = +0.694, t-test p < 0.001).
This table shows molecular features associated with FAM199X in patient tissues and cancer cell lines. In patient samples, FAM199X shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, FAM199X RNA and mutation anchors are most strongly linked to RNA-expression features, especially in STOMACH, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and UPPER_AERODIGESTIVE_TRACT.
